Trial Profile
A phase I, single-blind study to determine the safety, tolerability and pharmacodynamic profiles of a reference antigen combined with a new vaccine adjuvant (IMP321) versus the reference antigen alone and the reference vaccine in healthy young male volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Jul 2021
Price :
$35
*
At a glance
- Drugs Eftilagimod alpha (Primary) ; Hepatitis B vaccine; Hepatitis B vaccine; Hepatitis B vaccine recombinant
- Indications Hepatitis B
- Focus Adverse reactions
- Sponsors Immutep
- 30 Sep 2006 New trial record.